Identification of mild cognitive impairment subtypes predicting conversion to Alzheimer's disease using multimodal

Masataka Kikuchi1,2, Kaori Kobayashi1,3, Sakiko Itoh1

  • 1Department of Genome Informatics, Graduate School of Medicine, Osaka University, Osaka, Japan.

Insights

This study developed a new model to subtype mild cognitive impairment (MCI) patients and predict Alzheimer's disease (AD) conversion. The model identified distinct MCI subtypes with varying conversion risks and biological profiles.

Area of Science:

  • Neurology
  • Biostatistics
  • Medical Imaging

Background:

  • Mild cognitive impairment (MCI) is a precursor to Alzheimer's disease (AD) dementia.
  • MCI patients exhibit diverse pathologies and conversion rates to AD.
  • Accurate subtyping and prediction are crucial for early intervention and understanding disease mechanisms.

Purpose of the Study:

  • To develop a model for simultaneous subtyping of MCI subjects and prediction of conversion to AD dementia.
  • To analyze the distinct biological characteristics of each identified MCI subtype.
  • To improve the identification of individuals at high risk for AD progression.

Main Methods:

  • Utilized a heterogeneous mixture learning (HML) method to construct a decision tree-based model.
  • Integrated multimodal data: cerebrospinal fluid (CSF) biomarkers, structural MRI, APOE genotype, and age.
  • Evaluated model performance using F1 score and compared it with random forest and CART methods.

Main Results:

  • The HML model achieved an average F1 score of 0.721, outperforming CART and comparable to random forest.
  • Identified five distinct subtypes of MCI based on the HML decision tree.
  • Classified subtypes into low, moderate, and high conversion rate groups, with moderate groups further distinguished by CSF biomarkers or brain atrophy.

Conclusions:

  • The developed HML model effectively subtypes MCI and predicts AD conversion.
  • Distinct MCI subtypes possess unique biological profiles and varying rates of progression to AD.
  • This subtyping approach aids in identifying at-risk populations and understanding MCI heterogeneity.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
635
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
158
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
248